[Clinical double-blind study with two different dosages of maprotiline (150 and 225 mg per day) (author's transl)]
- PMID: 791194
- DOI: 10.1007/BF00369792
[Clinical double-blind study with two different dosages of maprotiline (150 and 225 mg per day) (author's transl)]
Abstract
Effects and side-effects of 150 mg and 225 mg maprotiline per day were compared by means of a double-blind trial in 20 depressed inpatients. The first 2 days patients received a high initial dosage of 300 mg per day. Patients were examined on days 0, 2, 5, 10, 15, 20, and 30. Symptoms were evaluated by the AMP system and the Hamilton scale for depressions. Laboratory examinations were carried out on days 0, 10, 20, and 30. Exanthemas developed in five patients, three of whom were on the higher dosage. Moreover, the lower dosage caused less fine hand tremor. Coinciding with the beginning of treatment a linear decrease of depressive symptoms was noted. This demonstrates the rapid onset of the antidepressant effect. Moreover, contrary to what has been stated for antidepressants generally, the onset of action was frequently noted well before 10-20 days of treatment. Some patients improved within a few days while others needed more time. The time lag until antidepressants influence depressive symptoms shows pronounced individual differences. No significant difference between the two dosages was found. The profiles show a better antidepressant effect for the higher dosage; however, because of a higher incidence of side-effects on the higher dosage of maprotiline, it cannot be recommended as routine. On the other hand, depressive inpatients should receive a daily dosage of at least 150 mg. Our findings suggest a dose-effect relationship for maprotiline.
Similar articles
-
Maprotiline: a review of its pharmacological properties and therapeutic efficacy in mental depressive states.Drugs. 1977 May;13(5):321-52. doi: 10.2165/00003495-197713050-00001. Drugs. 1977. PMID: 326531 Review. No abstract available.
-
A double-blind trial comparing mianserin and maprotiline in depressed inpatients.Clin Ther. 1985;7(5):584-92. Clin Ther. 1985. PMID: 3902238 Clinical Trial.
-
[Double blind study on maprotiline, an example of a multidimensional psychopharmacologic experiment (author's transl)].Pharmakopsychiatr Neuropsychopharmakol. 1978 Mar;11(2):63-7. doi: 10.1055/s-0028-1094563. Pharmakopsychiatr Neuropsychopharmakol. 1978. PMID: 347465 Clinical Trial. German.
-
Relationship between blood concentrations and clinical effects of a new antidepressant "maprotiline".Folia Psychiatr Neurol Jpn. 1980;34(2):147-56. doi: 10.1111/j.1440-1819.1980.tb01523.x. Folia Psychiatr Neurol Jpn. 1980. PMID: 7007180 Clinical Trial.
-
[Recurrence of unipolar depression and efficacy of maprotiline].Encephale. 1989 Nov-Dec;15(6):527-34. Encephale. 1989. PMID: 2693074 Review. French.
Cited by
-
Maprotiline: a review of its pharmacological properties and therapeutic efficacy in mental depressive states.Drugs. 1977 May;13(5):321-52. doi: 10.2165/00003495-197713050-00001. Drugs. 1977. PMID: 326531 Review. No abstract available.
-
Is dose escalation of antidepressants a rational strategy after a medium-dose treatment has failed? A systematic review.Eur Arch Psychiatry Clin Neurosci. 2005 Dec;255(6):387-400. doi: 10.1007/s00406-005-0579-5. Epub 2005 Apr 29. Eur Arch Psychiatry Clin Neurosci. 2005. PMID: 15868067